Cargando…

Rivastigmine improves dual-task gait velocity in patients with Alzheimer’s disease

BACKGROUND: Gait impairments are common in patients with Alzheimer’s disease. Cholinesterase inhibitors are used to treat the symptoms of patients with Alzheimer’s disease, but they have not been shown to reduce the severity of Alzheimer’s disease-related gait disorders. METHODS: This was a prospect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shimura, Hideki, Saiko, Aiba, Hayashi, Akito, Hattori, Nobutaka, Urabe, Takao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874473/ https://www.ncbi.nlm.nih.gov/pubmed/33568083 http://dx.doi.org/10.1186/s12883-021-02098-8

Ejemplares similares

Acute transient freezing of gait in a patient with posterior reversible encephalopathy syndrome
por: Nakajima, Asuka, et al.
Publicado: (2013)

New Alzheimer’s disease model mouse specialized for analyzing the function and toxicity of intraneuronal Amyloid β oligomers
por: Ochiishi, Tomoyo, et al.
Publicado: (2019)

Art and Parkinson’s disease: a dramatic change in an artist’s style as an initial symptom
por: Shimura, Hideki, et al.
Publicado: (2011)

Widespread enlarged perivascular spaces associated with dementia and focal brain dysfunction: case report
por: Taniguchi, Daisuke, et al.
Publicado: (2017)

CHANGES IN DUAL-TASK GAIT VELOCITY COST FOLLOWING CONCUSSION
por: Ernest, Kristin M., et al.
Publicado: (2021)

Using a Portable Gait Rhythmogram to Examine the Effect of Music Therapy on Parkinson’s Disease-Related Gait Disturbance
por: Gondo, Emiri, et al.
Publicado: (2021)

Rivastigmine in the treatment of Alzheimer’s disease: an update
por: Onor, Maria Luisa, et al.
Publicado: (2007)

Rivastigmine in the treatment of patients with Alzheimer’s disease
por: Müller, Thomas
Publicado: (2007)

Glycyl-alanyl-histidine protects PC12 cells against hydrogen peroxide toxicity
por: Shimura, Hideki, et al.
Publicado: (2017)

Marchiafava-Bignami disease mimics motor neuron disease: case report
por: Hoshino, Yasunobu, et al.
Publicado: (2013)

Cerebral Microbleeds Are Associated with Worse Cognitive Function in the Nondemented Elderly with Small Vessel Disease
por: Yamashiro, Kazuo, et al.
Publicado: (2014)

Rivastigmine in Alzheimer’s disease: Cognitive function and quality of life
por: Annicchiarico, Roberta, et al.
Publicado: (2007)

Once-daily transdermal rivastigmine in the treatment of Alzheimer’s disease
por: Wentrup, Andreas, et al.
Publicado: (2009)

Human-Derived Physiological Heat Shock Protein 27 Complex Protects Brain after Focal Cerebral Ischemia in Mice
por: Teramoto, Shinichiro, et al.
Publicado: (2013)

Phosphorylated recombinant HSP27 protects the brain and attenuates blood-brain barrier disruption following stroke in mice receiving intravenous tissue-plasminogen activator
por: Shimada, Yoshiaki, et al.
Publicado: (2018)

The relationship between motor recovery and gait velocity during dual tasks in patients with chronic stroke
por: Lee, Kyoung Bo, et al.
Publicado: (2015)

Influence of Rivastigmine transdermal on butyrylcholinesterase levels in patients with Alzheimer's disease
por: dos Santos, Gustavo Alves Andrade, et al.
Publicado: (2011)

Single-Task or Dual-Task? Gait Assessment as a Potential Diagnostic Tool for Alzheimer’s Dementia
por: Oh, Chorong
Publicado: (2021)

Efficacy of rivastigmine transdermal therapy on low food intake in patients with Alzheimer's disease: The Attitude Towards Food Consumption in Alzheimer's Disease Patients Revive with Rivastigmine Effects study
por: Tsuno, Norifumi, et al.
Publicado: (2019)

Effects of dance on gait and dual-task gait in Parkinson’s disease
por: Haputhanthirige, Nadeesha Kalyani Hewa, et al.
Publicado: (2023)

EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease*
por: Gauthier, S, et al.
Publicado: (2007)

Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer’s disease in daily practice
por: Seibert, Johannes, et al.
Publicado: (2012)

Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease
por: Ray, Balmiki, et al.
Publicado: (2020)

Comparative study of rivastigmine and galantamine on the transgenic Drosophila model of Alzheimer's disease
por: Siddique, Yasir Hasan, et al.
Publicado: (2022)

Effects of a priority-based dual task on gait velocity and variability in older adults with mild cognitive impairment
por: Lee, Jihye, et al.
Publicado: (2018)

The ReSPonD trial - rivastigmine to stabilise gait in Parkinson’s disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson’s disease who have fallen
por: Henderson, Emily J, et al.
Publicado: (2013)

Cognitive and motor dual task gait training improve dual task gait performance after stroke - A randomized controlled pilot trial
por: Liu, Yan-Ci, et al.
Publicado: (2017)

Longitudinally Extensive Transverse Myelitis with Intramedullary Metastasis of Small-Cell Lung Carcinoma: An Autopsy Case Report
por: Nishioka, Kenya, et al.
Publicado: (2013)

Development of new fusion proteins for visualizing amyloid-β oligomers in vivo
por: Ochiishi, Tomoyo, et al.
Publicado: (2016)

Multiple cerebral infarction diagnosed as Eosinophilic Granulomatosis with Polyangiitis by autopsy
por: Hira, Kenichiro, et al.
Publicado: (2019)

Impact of D-dimer for pathologic differentiation on transesophageal echocardiography in embolic stroke of undetermined source: a single-center experience
por: Hira, Kenichiro, et al.
Publicado: (2022)

Rivastigmine Improves Appetite by Increasing the Plasma Acyl/Des-Acyl Ghrelin Ratio and Cortisol in Alzheimer Disease
por: Furiya, Yoshiko, et al.
Publicado: (2018)

Esophagectasis Related to Rivastigmine
por: Sasaki, Osamu, et al.
Publicado: (2019)

Feasibility of dual‐task gait to estimate Alzheimer's related cognitive decline in Down syndrome
por: Van Pelt, Kathryn L., et al.
Publicado: (2020)

Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer’s disease
por: Ismail, Manal Fouad, et al.
Publicado: (2013)

Domperidone effective in preventing rivastigmine-related gastrointestinal disturbances in patients with Alzheimer’s disease
por: Kano, Osamu, et al.
Publicado: (2013)

The Effect of Rivastigmine Transdermal Patch on Sleep Apnea in Patients with Probable Alzheimer's Disease
por: Kim, Hyeyun, et al.
Publicado: (2016)

Correction: Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease
por: Ray, Balmiki, et al.
Publicado: (2020)

Effect of Rivastigmine on Mobility of Patients with Higher-Level Gait Disorder: A Pilot Exploratory Study
por: Gurevich, Tanya, et al.
Publicado: (2014)

The effect of gait speed and gait phase to the allocation of attention during dual task gait
por: Shimizu, Kotaro, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_26h8dvukj6flcfp5pt2gqtig57